title: Survival outcomes of First Nations patients with oral cavity squamous cell carcinoma (Poliquin 2014).
abstract: BACKGROUND
  Oral cavity squamous cell carcinoma (OCSCC) is the most common head and neck cancer, affecting approximately 2000 Canadians yearly. Analysis of Canadian Cancer Registry data has shown that the incidence of oral cavity cancer is decreasing and survival outcomes are improving. There are significant health disparities in First Nations (FN) people in Canada. The incidence of cancer in FN groups is significantly lower when compared to the general population, but the cancer-related morbidity and mortality is significantly higher. There is no Canadian literature currently for OCSCC, or any other head and neck cancer, that compares survival outcomes of FN to the overall population. Therefore, the objective of this study is to determine whether there is a difference in epidemiology and survival outcomes between FN and non-FN patients with OCSCC.
  
  
  METHODS
  This is a retrospective study of a population-based, prospectively-collected database from Alberta Cancer Registry (ACR). Patients with OCSCC, diagnosed and treated in Alberta between 1998 and 2009 were included. ACR data collected included patient gender, age at diagnosis, tobacco and alcohol use, FN status, TNM staging, performance status, date of death, cause of death, and follow-up. FN status was identified through the Alberta Health and Wellness registry and through postal code correlation for those who live on reserves.
  
  
  RESULTS
  A total of 583 patients with OCSCC were included in this study. Of these, 19 were identified as being FN, leaving 564 non-FN patients. When comparing the FN and non-FN groups, there is no significant difference in baseline demographics. Estimated yearly incidences for OCSCC in the Alberta population (all ages) and FN patients are 1.74/100,000 and 1.32/100,000 respectively (p = 0.23). Significant differences are seen in overall survival (OS) (5-year OS 58.1% for non-FN and 33.7% for FN) and for disease-specific survival (DSS) (5-year DSS 67.8% for non-FN and 44.5% for FN). Multivariate analysis confirmed FN patients have a significant increase risk of death in OS and DSS, with hazard ratios of 4.20 (p = 0.01) and 4.57 (p = 0.02), respectively.
  
  
  CONCLUSIONS
  The overall survival and disease specific survival are significantly lower in FN patients compared to non-FN patients with OCSCC.
authors: Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of Alberta, 1E4 Walter C Mackenzie Centre 8440-112 Street NW, Edmonton, AB, T6G 2B7, Canada. bree@ualberta.ca.
authors: Bree
authors: B
authors: Erickson
authors: Department of Otolaryngology-Head and Neck Surgery, University of California Davis, Sacramento, California, USA. vbiron@ualberta.ca.
authors: Vincent L
authors: VL
authors: Biron
authors: Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of Alberta, 1E4 Walter C Mackenzie Centre 8440-112 Street NW, Edmonton, AB, T6G 2B7, Canada. haz731@gmail.com.
authors: Han
authors: H
authors: Zhang
authors: Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of Alberta, 1E4 Walter C Mackenzie Centre 8440-112 Street NW, Edmonton, AB, T6G 2B7, Canada. Hadi.Seikaly@albertahealthservices.ca.
authors: Hadi
authors: H
authors: Seikaly
authors: Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of Alberta, 1E4 Walter C Mackenzie Centre 8440-112 Street NW, Edmonton, AB, T6G 2B7, Canada. entsurgeonalberta@gmail.com.
authors: David W J
authors: DW
authors: Côté
mesh_terms: D000328:Adult; D000368:Aged; D000416:Alberta; D002294:Carcinoma, Squamous Cell / Q000208:ethnology* / Q000401:mortality*; D002423:Cause of Death; D003431:Cross-Cultural Comparison; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000208:ethnology* / Q000401:mortality*; D016016:Proportional Hazards Models; D012042:Registries; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis
references: J Otolaryngol Head Neck Surg. 2011 Feb;40 Suppl 1:S65-9
references: 21453664
references: Int J Epidemiol. 2010 Feb;39(1):182-96
references: 19805488
references: Anticancer Drugs. 1993 Aug;4(4):419-29
references: 8400343
references: Arthritis Care Res (Hoboken). 2012 Nov;64(11):1715-9
references: 22623451
references: Open Med. 2012;6(4):e155-65
references: 23687531
references: J Otolaryngol Head Neck Surg. 2013;42:30
references: 23672952
references: Br J Cancer. 2003 Jul 21;89(2):232-8
references: 12865907
references: J Otolaryngol Head Neck Surg. 2013;42:28
references: 23663449
references: Cancer Causes Control. 2003 Apr;14(3):259-68
references: 12814205
references: Am J Clin Oncol. 1982 Dec;5(6):649-55
references: 7165009
references: Int J Circumpolar Health. 2004;63 Suppl 2:405-9
references: 15736694
references: Br J Cancer. 2003 Aug 4;89(3):431-6
references: 12888808
references: Head Neck. 1992 May-Jun;14(3):224-9
references: 1587740
references: Cancer Res. 1988 Jun 1;48(11):3282-7
references: 3365707
references: Health Rep. 2009 Dec;20(4):21-9
references: 20108603
references: J Clin Oncol. 2008 Feb 1;26(4):612-9
references: 18235120
references: J Otolaryngol Head Neck Surg. 2013 Apr 22;42(1):31
references: 23663568
references: Ann Surg Oncol. 2010 Jun;17(6):1471-4
references: 20180029
references: J Natl Cancer Inst. 2007 May 16;99(10):777-89
references: 17505073
references: Otolaryngol Head Neck Surg. 2012 Jul;147(1):74-8
references: 22328702
references: J Cancer Educ. 2012 Apr;27(1 Suppl):S73-9
references: 22281722
references: Clin J Am Soc Nephrol. 2013 Jul;8(7):1188-94
references: 23449766
references: N Engl J Med. 2010 Jul 1;363(1):24-35
references: 20530316
references: Cancer. 2008 Sep 1;113(5 Suppl):1256-65
references: 18720381
references: Arthritis Care Res (Hoboken). 2012 Jan;64(1):138-43
references: 21972194